{"nctId":"NCT02871440","briefTitle":"A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye","startDateStruct":{"date":"2016-09-19","type":"ACTUAL"},"conditions":["Dry Eye Syndromes"],"count":40,"armGroups":[{"label":"Eye drop 1","type":"EXPERIMENTAL","interventionNames":["Drug: Omega 3"]},{"label":"Eye drop 2","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Optive Advanced"]},{"label":"Eye drop 3","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Optive"]}],"interventions":[{"name":"Omega 3","otherNames":[]},{"name":"Optive Advanced","otherNames":[]},{"name":"Optive","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;\n* Over 18 years of age;\n* Not wearing contact lenses in the past 3 months before enrolling\n* Willing to use eye drops and comply with the study visit schedule as directed by the Investigator;\n* Habitual (corrected or uncorrected) visual acuity of 6/9.5 or better in each eye;\n* At the Screening visit (Day -14), patients must have Ocular Surface Disease Index (OSDI) score \\>18 (0 to 100 scale). At Baseline (Day 1) visits, patients must have OSDI score \\> 12 to continue in the study.\n* TBUT≤10sec in at least 1 eye at Screening visit and Baseline visit\n* Corneal sodium fluorescein staining score ≥ 1 and \\<4 (Oxford scheme) at Screening and Baseline visit.\n\nExclusion Criteria:\n\n* Schirmer test (with anesthesia) ≤ 2 mm in either eye at Screening\n* Patients who are currently using topical ocular medication or have used topical ocular medication within 2 weeks of the Screening visit. Patients who are being treated bilaterally with a marketed artificial tear for dry eye can be considered, provided they discontinue use at the Screening visit;\n* Any active anterior segment disease excluding blepharitis;\n* Any systemic disease that may affect ocular health e.g. Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis and systemic lupus erythematosus;\n* History of epilepsy or migraines exacerbated by flashing, strobe-like lights;\n* Rigid or soft contact lens wearer, including orthokeratology;\n* History of eye surgery within 6 months prior to enrolment in the study;\n* Previous corneal refractive surgery","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Tear Evaporation Rate","description":"Measured using a Vapometer (g/m\\^2\\*h)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":"42.4"},{"groupId":"OG001","value":"67","spread":"31.7"},{"groupId":"OG002","value":"75.3","spread":"38.0"}]}]}]},{"type":"SECONDARY","title":"Tear Break-up Time","description":"Measured with fluorescein dye (seconds)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.10","spread":"2.76"},{"groupId":"OG001","value":"6.52","spread":"2.94"},{"groupId":"OG002","value":"6.22","spread":"2.73"}]}]}]},{"type":"SECONDARY","title":"Subjective Ocular Comfort","description":"Measured using visual analogue scales (0-100); 0 indicates no/less symptoms and 100 indicates maximum/worse symptoms.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":"23.73"},{"groupId":"OG001","value":"21","spread":"23.89"},{"groupId":"OG002","value":"21","spread":"23.73"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["Ocular irritation","Bacterial Chest Infection","Itchy and uncomfortable eyes","Burning and Stinging in the eye","Anemia and Vitamin D Deficiency"]}}}